Table 3 CTC-organoid established to date
From: The functional and clinical roles of liquid biopsy in patient-derived models
Tumor type | Stage | CTC counts | Enrichment and characterization | Culture condition | Number | Success rate (%) | References |
|---|---|---|---|---|---|---|---|
PCa | Castration-resistant |  > 100/8 ml | RosetteSep | Advanced DMEM/F12 | 1 | N/A | [16] |
Metastatic |  >  = 5/7.5 ml EpCAM+ (CellSearch) | DLA + RosetteSep + CellSearch/DLA + RosetteSep | Adjusted prostate cancer organoid medium (APCOM) | 14 | 35 | [67] | |
Lung cancer | Early-stage | 1–11/1 ml CK7/8 (confocal) | A microfluidic CTC-capture device | With fibroblasts extracellular matrix on a microfluidic chip | 14 | 73 | [68] |
SCLC | Limited-stage or extensive-stage | 8–433/7.5 ml IsoFlux | RosetteSep | In DMEM/F12 medium on binary colloidal crystals | 18 | 81.8 | [69] |
HNC | Stage I–IV | N/A | RosetteSep | Seeded onto a binary colloidal crystal (BCC) substrate and cultured in DMEM/F12 medium | 37 | 92.50 | [70] |
PDAC | Stage II–IV | N/A | RosetteSep | Seeded onto a binary colloidal crystal (BCC) substrate and cultured in DMEM/F12 medium | 36 | 87.8 | [71] |